Two Distinct Humanized Monoclonal Antibodies for Immunotherapy of Ovarian Cancer
- *Corresponding Author:
- Gregory Lee, Ph.D
9117 Shaughnessy Street, Vancouver, V6P 6R9, Canada
E-mail: [email protected]
Received Date: February 20, 2014; Accepted Date: March 27, 2014; Published Date: March 31, 2014
Citation: Lee G, Huang C, Ge B (2014) Two Distinct Humanized Monoclonal Antibodies for Immunotherapy of Ovarian Cancer. J Cancer Sci Ther 6:110-116. doi: 10.4172/1948-5956.1000258
Copyright: © 2014 Lee G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Two monoclonal antibodies (Mab) were selected for development of anti-cancer drugs targeting ovarian cancer. RP215 Mab was shown to react with a carbohydrate-associated epitope detected mainly in the heavy chains of cancer cell-expressed immunoglobulins which are essential for the growth/proliferation of almost all human cancer cells. GHR106 Mab, on the other hand, reacts specifically with GnRH receptor on the surface of almost all cancer cells. In this review, efforts were made to use an ovarian cancer cell line, OC-3-VGH as the experimental model to study these two Mabs in murine and humanized isoforms including humanization, comparative biochemical and immunological characterizations. Surface binding of either of these two Mabs can result in apoptosis and complement-dependent cellular cytotoxicity to this ovarian cancer cell line and others. Both murine Mabs were humanized and shown to be bioequivalent with respect to affinity and biospecificity to their murine counterparts through extensive biochemical/immunological studies. Therefore, preclinical and clinical studies were warranted to continue the investigations of these two potential anti-cancer drug candidates for therapeutic treatments of ovarian cancer.